drugset
Drugs / CT125A cells
last change Feb 2026 re-read 9 days ago

CT125A cells

also known as CT125A

Cell therapy targets CD5 via depletion

Developed for
B-cell chronic lymphocytic leukemia · diffuse large B-cell lymphoma · follicular lymphoma · mantle cell lymphoma · peripheral T-cell lymphoma, not otherwise specified · refractory hematologic cancer
Investigated by
Huazhong University of Science and Technology · Shanghai IASO Biotechnology Co., Ltd

Trials 1

today NCT04767308 · Ph 0
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT04767308 Mar 2021 → Sep 2023 B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +2 Huazhong University of Science and Technology Unknown No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2021-08-13 Nanjing IASO Biotechnology Co., Ltd. Results IASO Biotherapeutics Publishes Preclinical Results of Its CD5-Targeting CAR-T in Molecular Therapy iasobio.com ↗

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as CT125A cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04767308 ↗
Known as CT125A “This phase 1 trial evaluates autologous CD5-targeting CAR-T cells with CD5 gene deletion (CT125A) in seven patients with relapsed/refractory CD5+ hematologic malignancies.” PMID 41633358 ↗ Feb 2026
Action Deplete “Post-infusion immunophenotyping shows persistent depletion of CD5+ T cells and CD19+ B cells” PMID 41633358 ↗ Feb 2026
Modality Cell therapy “This phase 1 trial evaluates autologous CD5-targeting CAR-T cells with CD5 gene deletion (CT125A) in seven patients with relapsed/refractory CD5+ hematologic malignancies.” PMID 41633358 ↗ Feb 2026
Route Intravenous “After lymphodepletion, subjects will receive one dose treatment with CT125A cells by intravenous (IV) infusion.” NCT04767308 ↗
Target CD5 “This phase 1 trial evaluates autologous CD5-targeting CAR-T cells with CD5 gene deletion (CT125A) in seven patients with relapsed/refractory CD5+ hematologic malignancies.” PMID 41633358 ↗ Feb 2026